Major study of hypermutated gliomas published in Nature

Major study of hypermutated gliomas published in Nature - Hallo friendsTOP POLENNEWS, In the article you read this time with the title Major study of hypermutated gliomas published in Nature, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : Major study of hypermutated gliomas published in Nature
link : Major study of hypermutated gliomas published in Nature

Read too


Major study of hypermutated gliomas published in Nature

Mechanisms and therapeutic implications of hypermutation in gliomas.
https://www.ncbi.nlm.nih.gov/pubmed/32322066

Unfortunately this study provides negative evidence to the idea that hypermutated gliomas would be more responsive to treatment with PD-1 blockers such as nivolumab and pembrolizumab.

from the study
"MMR-deficient gliomas were characterized by a lack of prominent T cell infiltrates, extensive intratumoral heterogeneity, poor patient survival and a low rate of response to PD-1 blockade. "

"Because our prior analyses indicated that patients with hypermutated gliomas might have reduced survival, we used a second set of historical controls to compare the outcome of hypermutated gliomas treated with PD-1 blockade versus other systemic agents. Unexpectedly, we observed a longer median OS for patients treated with other systemic agents when compared to those treated with PD-1 blockade"

However, the mismatch repair deficient, hypermutated tumor cells were sensitive to the chemotherapy agent CCNU (lomustine).

"We next treated native and engineered isogenic MMR-knockout glioma models with temozolomide or the nitrosourea lomustine (CCNU), a chloroethylating alkylating agent that generates DNA interstrand crosslinks and double-strand breaks (Fig. 2c, Extended Data Fig. 8g–i). All MMR-deficient models were resistant to temozolomide and sensitive to CCNU, consistent with the lack of hypermutation in samples from nitrosourea-treated patients"


This confirms advice I've given to patients with temozolomide-driven hypermutated recurrent gliomas: CCNU (lomustine) chemotherapy is probably the best choice in terms of conventional chemotherapy options.  However it argues against advice that PD-1/PD-L1 blockade (drugs such as pembrolizumab or nivolumab) would be the best option.


Thus Article Major study of hypermutated gliomas published in Nature

That's an article Major study of hypermutated gliomas published in Nature This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Major study of hypermutated gliomas published in Nature with the link address https://polennews.blogspot.com/2020/04/major-study-of-hypermutated-gliomas.html

Subscribe to receive free email updates:

Related Posts :

0 Response to "Major study of hypermutated gliomas published in Nature"

Post a Comment